![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Foundation Medicine’s Lung Cancer Diagnostic Approved
Foundation Medicine’s Lung Cancer Diagnostic Approved
Cambridge, Mass.-based Foundation Medicine has received the FDA’s approval for its FoundationOne CDx diagnostic device for lung cancer.
The product is intended as a companion diagnostic for Takeda Oncology’s oncology drug Alunbrig (brigatinib), which is approved for treatment of adults with anaplastic lymphoma kinase-positive metastatic nonsmall-cell lung cancer.
FoundationOne CDx is a tissue-based genomic test that can detect this type of cancer and identify patients who may be appropriate for treatment with Alunbrig.
Upcoming Events
-
21Oct